Valuation: Arrowhead Pharmaceuticals, Inc.

Market Cap 9.98B 8.65B 8.18B 7.4B 13.89B 958B 14B 97.57B 37.54B 486B 37.5B 36.67B 1,548B P/E 2026 *
-19.4x
P/E 2027 * -15.3x
Enterprise Value 9.15B 7.93B 7.49B 6.79B 12.73B 878B 12.83B 89.44B 34.41B 445B 34.37B 33.61B 1,419B EV / Sales 2026 *
19.8x
EV / Sales 2027 * 27.4x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -
1 day-12.40%
1 week-16.97%
Current month-14.23%
1 month-18.43%
3 months-8.40%
6 months+28.37%
Current year+6.45%
1 week 70.6
Extreme 70.605
85.98
1 month 70.6
Extreme 70.605
90.21
Current year 54.02
Extreme 54.02
95.49
1 year 29.04
Extreme 29.04
95.49
3 years 9.57
Extreme 9.57
95.49
5 years 9.57
Extreme 9.57
95.49
10 years 1.2
Extreme 1.2
95.49
Manager TitleAgeSince
Chief Executive Officer 56 2007-11-30
Director of Finance/CFO - 2025-05-12
Chief Tech/Sci/R&D Officer - 2022-07-31
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 2010-08-18
Director/Board Member 66 2011-12-18
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/26 Sell

Director

-2,000 0.0014%
8/18/26 Sell

Director

-11,600 0.0082%
6/15/26 Free

Director

11,882 0.0084%
Change 5-day change 1-year change 3-year change Capi.($)
-12.40%-16.97%+146.49%+144.36% 9.98B
-1.38%+0.20%+46.42%+96.33% 69.18B
-0.19%-0.83%+36.06%+75.75% 62B
-4.29%-3.98%-16.22%+350.66% 26.19B
+1.79%+2.48%+29.13%+14.79% 25.75B
-2.20%-2.00%-1.22%-14.48% 24.29B
+3.47%-0.69%+20.85%-19.42% 19.84B
+1.26%-14.23%+170.04%+298.75% 15.65B
-5.54%+0.69%-8.13%+830.48% 13.88B
-0.65%-4.49%-10.10%+453.49% 14.09B
Average -2.02%-3.67%+41.33%+223.07% 28.09B
Weighted average by Cap. -1.23%-1.87%+35.70%+157.46%

Financials

2026 *2027 *
Net sales 461M 399M 378M 342M 642M 44.24B 647M 4.51B 1.73B 22.43B 1.73B 1.69B 71.54B 340M 294M 278M 252M 473M 32.61B 477M 3.32B 1.28B 16.53B 1.28B 1.25B 52.73B
Net income -518M -449M -425M -384M -722M -49.74B -727M -5.07B -1.95B -25.22B -1.95B -1.9B -80.43B -650M -563M -532M -482M -904M -62.31B -911M -6.35B -2.44B -31.59B -2.44B -2.39B -101B
Net Debt -832M -721M -682M -617M -1.16B -79.84B -1.17B -8.14B -3.13B -40.48B -3.13B -3.06B -129B -683M -591M -559M -506M -950M -65.5B -957M -6.67B -2.57B -33.21B -2.56B -2.51B -106B
Logo Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
711
Date Price Change Volume
26-09-15 US$70.67 -12.40% 4,371,136
26-09-14 US$80.67 -2.63% 1,329,213
26-09-11 US$82.85 +0.11% 1,335,818
26-09-10 US$82.76 +0.16% 1,020,398
26-09-09 US$82.63 -2.91% 3,668,389
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
70.67USD
Average target price
110.00USD
Spread / Average Target
+55.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARWR Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!